A Phase 2 interventional study of Lactiplantibacillus plantarum 299v and Placebo Capsule(s) in Iron Deficiency (ID) and Pregnancy, sponsored by University of Illinois Chicago. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by University of Illinois Chicago · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Iron Deficiencies with a site in United States — 16 open to participants now, 20 under way, 4 of them phase 3. Iron Deficiencies · United States.
Among the 82 studies in Iron Deficiencies with a site in United States, this one is the 10th largest by planned enrollment of the 63 interventional ones that give a count, is one of 8 that started in 2026, is one of 8 in phase 2, reaches primary completion later than 19 of the 19 other live ones, and was the 70th registered.
386 studies on the registry are indexed under Iron Deficiencies; 78 are open to participants now.
Browse Iron Deficiencies studies →16 of the 82 studies in Iron Deficiencies with a site in United States are open now. Recruiting first, the newest first:
Qualia Life Sciences · Sites in United States
Ages 18+ · Healthy volunteers
Lindenwood University · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
Kaiser Permanente · Sites in United States
Ages 18+
Pennington Biomedical Research Center · Sites in United States
Ages 18–50 · Healthy volunteers
Columbia University · Sites in United States
Ages 10–19
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 53 Iron Deficiencies studies recruiting now, 23 (43%) set no upper age limit and 26 (49%) stop at 75 or younger; 14 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 14 · Phase 4 10
First in 2000; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 99 across 301 interventional studies indexed under Iron Deficiencies.
Median enrollment 89 across the 63 interventional studies, 73 across the 18 observational. Of the 57 that completed or were terminated, 13 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 82 have an industry lead sponsor. The 10 most frequent:
University of Illinois Chicago is the lead sponsor of 31 studies on the registry; 19 are open to participants now.
University of Illinois Chicago has 1 study filed under Iron Deficiencies — fewer than ten, so there is no comparison to draw.
10 of the studies in Iron Deficiencies with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05179226Phase 3Pharmacosmos A/SMulti-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia | 2027-04-30 |
| NCT07217873Phase 3Columbia UniversityIntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study | 2027-08-31 |
| NCT06527391Phase 3University of MinnesotaCholine and Iron Deficiency | 2027-09-21 |
| NCT07197905Vanderbilt University Medical CenterRestoring Iron Deficiency in POTS | 2026-12 |
| NCT07892911Ancestral Supplements, LLCA Study to Evaluate the Effects of a Beef Liver Supplement on Energy, Mood, and Mental Clarity | 2026-12-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 82 studies in Iron Deficiencies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Maternal iron deficiency (ID) and iron deficiency anemia (IDA) is associated with maternal and infant mortality, spontaneous preterm birth, maternal postpartum hemorrhage, and neurocognitive defects in the neonate. Therefore, preventing maternal IDA in at-risk women is critical. The standard approach to improving iron status in pregnancy (i.e., oral iron supplements) is suboptimal and gastrointestinal discomforts associated with this approach (i.e., constipation) impairs adherence. The incidence of ID (18%) and IDA (5%) in pregnant populations suggest alternative interventions are needed to optimize iron status in pregnancy. There is increasing evidence that consuming the probiotic Lactoplantibacillus plantarum 299v (LP299V®) can enhance dietary non-heme iron absorption by changes in the composition and metabolic patterns of gut microbiota that reduce intestinal pH, enhance mucin production and favor an anti-inflammatory milieu. This immunomodulatory effect may be important because inflammation stimulates hepatic production of hepcidin, a master regulator of systemic iron homeostasis, which inhibits iron flow into circulation from diet and body stores. Further, the effects of LP299V® may extend to the placenta. The investigators' team showed previously that maternal iron deficiency is associated with changes to placental iron metabolism with more iron sequestered in the placenta and less iron transferring to the fetus. Given its positive effects on maternal iron status, the investigators surmise that LP299V® supplementation will result in higher placenta protein expression of iron transporters, transferrin receptor-1 and ferrroportin-1, and lower placental iron accumulation/content. The primary goal of this study is to test the efficacy of this low-cost, safe, innovative approach to optimizing maternal iron status in individuals at risk for ID in pregnancy [Hb 11.0 - 11.9 g/dL (first trimester) and Hb 10.5 - 11.5 g/dL (second trimester) based on new OB clinical complete blood count (CBC) results obtained from the EHR] from 10-16 weeks gestational age (GA) until the time of labor. The investigators will also test the effects on neonatal (cord blood) iron status and (cord blood + newborn heel stick) Hb at birth and determine the effect of maternal LP299V® supplementation on the maternal gut microbiome, hepcidin-ferroportin axis and placenta iron and placenta transport of iron as its primary mechanisms of action. Finally, the investigators will explore the effect of maternal LP299V® supplementation on infant neurodevelopment at birth. This study is an essential first step toward evaluating if twice daily oral LP299V® is an efficacious, safe, inexpensive, and scalable clinical strategy for the prevention of maternal ID and its related complications in at-risk women.
The criteria were revised on the registry on Nov 2, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Probiotic
Dietary Supplement: Lactiplantibacillus plantarum 299v
Placebo capsule
Other: Placebo Capsule(s)
Probiotic
Placebo control
Maternal hemoglobin from complete blood count (CBC) with differential
Venous blood draw
Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
Maternal iron deficiency anemia (IDA)
Hb \<10.5 g/dL during second trimester and Hb \<11 g/dL during third trimester
Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
Complete blood count (CBC) with differential (WBC, RBC, Hematocrit, MCV, MCH, MCHC, RDW, Platelet Count, MPV and Differential (Absolute and Percent - Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils)
Venous blood draw
Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
Maternal serum ferritin
Venous blood draw
Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
Maternal serum iron
Venous blood draw
Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
Maternal sTfR
Venous blood draw
Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
Maternal total body iron (TBI)
(TBI (mg/kg) = - \[log(TfR/ferritin ratio) - 2.8229\]/0.1207)
Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
Maternal hepcidin
Venous blood draw
Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
Maternal erythropoietin (EPO)
Venous blood draw
Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
Maternal circulating cytokines (interleukin-6 (IL-6), GM-CS, IL-2, IL-4, IL-8, IL-10, TNFα, and IFNγ
Venous blood draw
Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
Maternal C-reactive protein (CRP)
Venous blood draw
Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
Maternal Erythroferrone (ERFE)
Venous blood draw
Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
Maternal Erythroferrone (ERFE) Cord Complete blood count (CBC) with differential (WBC, RBC, Hematocrit, MCV, MCH, MCHC, RDW, Platelet Count, MPV and Differential (Absolute and Percent - Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils)
Cord blood draw
Time frame: delivery
Cord serum ferritin
Cord blood draw
Time frame: delivery
Cord serum iron
Cord blood draw
Time frame: delivery
Cord sTfR
Cord blood draw
Time frame: delivery
Cord total body iron (TBI)
(TBI (mg/kg) = - \[log(TfR/ferritin ratio) - 2.8229\]/0.1207)
Time frame: delivery
Newborn heel stick
Blood spot
Time frame: After delivery before baby released home
Placenta iron transporter (FPN-1 and TFR-1)
Western blot
Time frame: delivery
Placenta iron quantification
Immunohistochemistry
Time frame: delivery
Placenta tissue iron concentration
Inductively coupled plasma-mass spectrometry (ICP-MS)
Time frame: delivery
Fecal abundance of A. muciniphila
Quantitative polymerase chain reaction (qPCR)
Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3), delivery (V4)
Shot-gun sequencing and analysis (taxonomy and functional profiling)
MetaPhlAn4 and HUMAnN 2.0
Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
Microbial mucin degrading enzymes
CaZymes
Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
Stool pH
pH probe
Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
Adverse pregnancy outcomes post-treatment and at delivery (clinical- EMR)
Adverse pregnancy outcomes post-treatment and at delivery (clinical-EMR)
Time frame: delivery
Probiotic acceptance and tolerability
Daily capsule adherence Reported adverse health effects
Time frame: 10-22 weeks GA, 14-20 weeks GA, 18-24 weeks GA, 22-28 weeks GA, 26-32 weeks GA, 30-36 weeks GA, 34-40 weeks GA, 38-40 weeks GA
Auditory Brainstem Response (ABR) testing
Interpeak latency I-V
Time frame: -3 days postpartum
Habitual and recent dietary intake
Food frequency (baseline only) questionnaire and 24-hour diet recall
Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
Physical activity
Self-report questionnaire
Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
Infant characteristics (clinical-EMR)
Infant sex, weight, gestational age (clinical-EMR)
Time frame: delivery
Pre-pregnancy body mass index (BMI)
Self-report (confirmed by clinical-EMR, if possible) BMI will be calculated as kg/m2
Time frame: Up to 6 months before pregnancy
Gestational weight gain
Gestational weight gain
Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
Gut microbiome factors
Questionnaire related to allergies, diet, travel, and environment
Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
Presence of probiotic strain in stool
Quantitative polymerase chain reaction (qPCR)
Time frame: 10-22 weeks GA (V1), 22-28 weeks GA (V2), 30-36 weeks GA (V3)
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Oct 2030, 56 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lactiplantibacillus plantarum 299V
University of Illinois Chicago